Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

The first head-to-head trial shows Mounjaro helps people lose more weight than its rival Wegovy as scientists confirm why it ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Clooney also addressed the fallout from his New York Times op-ed calling for then-President Biden to exit the presidential race.